{"protocolSection":{"identificationModule":{"nctId":"NCT01762163","orgStudyIdInfo":{"id":"QZTL2013"},"secondaryIdInfos":[{"id":"QZTL","type":"REGISTRY","domain":"QZTL"}],"organization":{"fullName":"China Academy of Chinese Medical Sciences","class":"OTHER"},"briefTitle":"Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke","officialTitle":"Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke With Qi Deficiency and Blood Stasis Syndrome: a Multicenter, Randomized,Double-blind，Placebo- and Active-controlled Adaptive Study"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-10"},"primaryCompletionDateStruct":{"date":"2016-10","type":"ACTUAL"},"completionDateStruct":{"date":"2016-10","type":"ACTUAL"},"studyFirstSubmitDate":"2013-01-04","studyFirstSubmitQcDate":"2013-01-04","studyFirstPostDateStruct":{"date":"2013-01-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-11","lastUpdatePostDateStruct":{"date":"2016-10-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Zhong Wang","investigatorTitle":"Professor","investigatorAffiliation":"China Academy of Chinese Medical Sciences"},"leadSponsor":{"name":"China Academy of Chinese Medical Sciences","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a 20-week study consisting of a 12-week multicenter, randomized,double-blind adaptive study to compare efficacy and safety of Qizhitongluo Capsule,Naoxintong Capsule and placebo in the recovery phase of ischemic stroke with qi deficiency and blood stasis syndrome, and a 8-week post-treatment safety follow-up.After 312 patients complete 12 weeks of treatment there will be an interim analysis."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Ischemic Stroke,adaptive design, randomized, double-blind"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":622,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Qizhitongluo Capsule","type":"EXPERIMENTAL","description":"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.\n\nintervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks.","interventionNames":["Drug: Qizhitongluo Capsule","Drug: Aspirin Enteric-coated Tablets","Behavioral: the routine recovery training","Drug: placebo"]},{"label":"Naoxintong Capsule","type":"ACTIVE_COMPARATOR","description":"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.\n\nintervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks.","interventionNames":["Drug: Naoxintong Capsule","Drug: Aspirin Enteric-coated Tablets","Behavioral: the routine recovery training"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.\n\nintervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks.","interventionNames":["Drug: Aspirin Enteric-coated Tablets","Behavioral: the routine recovery training","Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"Qizhitongluo Capsule","armGroupLabels":["Qizhitongluo Capsule"],"otherNames":["QZTL group"]},{"type":"DRUG","name":"Naoxintong Capsule","armGroupLabels":["Naoxintong Capsule"],"otherNames":["NXT group"]},{"type":"DRUG","name":"Aspirin Enteric-coated Tablets","armGroupLabels":["Naoxintong Capsule","Placebo","Qizhitongluo Capsule"]},{"type":"BEHAVIORAL","name":"the routine recovery training","armGroupLabels":["Naoxintong Capsule","Placebo","Qizhitongluo Capsule"]},{"type":"DRUG","name":"placebo","armGroupLabels":["Placebo","Qizhitongluo Capsule"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"change in the Lower Extremity Fugl-Meyer score","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."}],"secondaryOutcomes":[{"measure":"Change in Aphasia Quotient（AQ) score","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."},{"measure":"Change in Barthel Index score and proportion of subjects with Barthel Index score ≥90","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."},{"measure":"Change in the Upper Extremity Fugl-Meyer score","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."},{"measure":"Change in the total Fugl-Meyer motor score","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."},{"measure":"Change in the syndrome score of Qi Deficiency and Blood Stasis","timeFrame":"baseline, after 4,12 weeks of treatment, after 90 days of onset."},{"measure":"the incidence of New-onset cardiovascular events","timeFrame":"during the 20-weeks"},{"measure":"Changes in plasma glucose and lipid concentrations and blood coagulate","timeFrame":"baseline and after 12 weeks of treatment"},{"measure":"physical examination、 laboratory tests and ECG","timeFrame":"baseline and after 12 weeks of treatment"},{"measure":"the incidence of adverse events","timeFrame":"during the 20-weeks"},{"measure":"all cause mortality","timeFrame":"during the 20-weeks"}],"otherOutcomes":[{"measure":"The modified Rankin Scale(mRS) score","timeFrame":"baseline"},{"measure":"the National Health Interview Surveys (NHISS) score","timeFrame":"baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age≥35 years and \\<80 years;\n* Diagnosis of ischemic stroke in recovery phase, according to the Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2010;\n* Diagnosis of ischemic stroke with qi deficiency and blood stasis syndrome;\n* The interval from the onset to recruitment was 15-28 days;\n* FM score \\<90 or AQ\\<93.8 and diagnosis of aphasia;\n* Diagnosis of cerebral anterior circulation obstruction;\n* 4≤ NIHSS score\\<20;\n* Patient is willing to participate voluntarily and to sign a written patient informed consent.\n\nExclusion Criteria:\n\n* Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.) on CT or MRI.\n* Known history of allergy or suspected allergic to the study drugs.\n* Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.\n* Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.\n* Cerebral embolism caused by cerebral tumor, cerebral trauma, cerebral parasitosis, rheumatic heart disease, coronary heart disease or other cardiac diseases complicated with atrial fibrillation.\n* Prestroke score on the mRS ≥2.\n* Space-occupying lesions, CT or MRI revealed midline structure shift; CT revealed that massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery.\n* Disable patients prescribed by law（blind, deaf, dumb, mental retardation, mental disorders and physical disabilities which due to other causes affect neural function deficient scale).\n* Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.\n* Suspected addicted into alcohol or drug abuse; with severe complications that would make the condition more complicated assessed by the investigator.\n* Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent.\n* Patient who is participating in other trials or has been participated in other trials in recent 3 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Zhong Wang, Ph.D.","affiliation":"Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences","role":"STUDY_DIRECTOR"},{"name":"Yingzhen Xie, M.D.","affiliation":"Dongzhimen Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The First Affiliated Hospital of Guangxi University of Chinese Medicine","city":"Nanning","state":"Guangxi","zip":"530023","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"Langfang TCM Hospital","city":"Langfang","state":"Hebei","country":"China","geoPoint":{"lat":39.50972,"lon":116.69472}},{"facility":"Luohe Hospital of Chinese Medicine","city":"Luohe","state":"Henan","zip":"462000","country":"China","geoPoint":{"lat":33.56394,"lon":114.04272}},{"facility":"the First affiliated Hospital of Henan University of TCM","city":"Zhengzhou","state":"Henan","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"the affiliated Hospital to Changchun University of Chinese Medicine","city":"Changchun","state":"Jilin","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"201 Hospital of People's Liberation Army","city":"Dalian","state":"Liaoning","country":"China","geoPoint":{"lat":38.91222,"lon":121.60222}},{"facility":"Zhongshan Hospital Dalian University","city":"Dalian","state":"Liaoning","country":"China","geoPoint":{"lat":38.91222,"lon":121.60222}},{"facility":"Second Hospital affiliated to Liaoning University of Traditional Chinese Medicine","city":"Shenyang","state":"Liaoning","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Teaching Hospital of Chengdu University of Traditional Chinese Medicine","city":"Chengdu","state":"Sichuan","zip":"610075","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"West China Hospital,Sichuan University","city":"Chengdu","state":"Sichuan","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","city":"Beijing","zip":"100700","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Guang'anmen Hospital Nan District,China Academy of Chinese Medical Sciences","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"First Teaching Hospital of Tianjin University of TCM","city":"Tianjin","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M4736","name":"Blind Loop Syndrome","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}